Search Results
Your search for ,wHo matches 21253 pages
Showing 1251 - 1300Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
Palbociclib Plus Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative Metastatic Breast Cancer
In an overall survival analysis of a South Korean phase II trial (Young-PEARL) reported in The Lancet Oncology, Ahn et al found no benefit with palbociclib plus exemestane and leuprorelin vs capecitabine in premenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast...
Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase...
Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction
Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...
Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk
Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background Gastric cancer is the fourth...
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early HER2-Positive Breast Cancer
In an analysis from the ShortHER trial reported in JAMA Oncology, Dieci et al identified 10-year outcomes with 9 weeks or 1 year of adjuvant trastuzumab plus chemotherapy according to level of tumor-infiltrating lymphocytes (TILs) in patients with early HER2-positive breast cancer. Study Details...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
Participation in Early Trials May Provide Some Patients With Access to Cancer Drugs Later FDA Approved
Nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that eventually receive U.S. Food and Drug Administration (FDA) approval, according to a recent study published by Ouimet et al in the Journal of the National Cancer Institute. The findings may have...
BRCA1 Gene Mutations May Not Be Key to Prostate Cancer
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
New Study Uncovers Low Uptake of Supportive Care at End of Life in Patients With Advanced Cancer
Investigators have found that nearly 50% of patients with advanced cancer may receive potentially aggressive treatment at the expense of supportive care, despite considerable efforts to improve the quality of end-of-life care in the United States, according to a recent study published by Kwon et al ...
Physical Activity May Help Colorectal Cancer Survivors Live as Long as Those in General Population
Physical activity may help colorectal cancer survivors achieve long-term survival rates comparable to those of individuals in the general population, according to a recent study published by Brown et al in Cancer. Background Patients with colorectal cancer often face higher rates of premature...
Immunotherapy for Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
In a single-center retrospective study reported in JAMA Oncology, Lochrin et al identified activity of ipilimumab/nivolumab in melanoma brain metastases after progression on anti–PD-1 treatment. Study Details The study involved 28 patients with prior PD-1 inhibitor treatment who developed...
The Death of Alexei Navalny and the Discovery of Cancer Chemotherapy
Remembering Alexi Anatolyevich Navalny: The Russian opposition leader, lawyer, anticorruption activist, and political prisoner, Alexi Navalny died in the Arctic Wolf prison in Siberia approximately 1 year ago on February 16, 2024. He was designated a Prisoner of Conscience by Amnesty...
Ageism and Its Role in the Treatment of Cancer
Age discrimination, often referred to as ageism, is an increasingly pressing issue within society. Although it can impact individuals across all age groups, older adults are particularly vulnerable. According to the U.S. Census Bureau projections, by 2040, individuals aged 65 and older will...
Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer
Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...
Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...
Cryotherapy With Taxane Infusion: Strategy for Preventing Peripheral Neuropathy in Breast Cancer
In a meta-analysis reported in the journal Breast Cancer Research and Treatment, Kumar et al found that the use of cryotherapy decreased the incidence of moderate or worse peripheral neuropathy by more than 50% in patients with breast cancer who received paclitaxel or nab-paclitaxel. Cryotherapy...
Case 3: Relapsed/Refractory Nodal Marginal Zone Lymphoma
This is Part 3 of Evolving Treatment Landscape of Indolent Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Laurie Sehn, Gilles Salles, and Sonali Smith discuss the treatment of relapsed/refractory nodal marginal zone...
Case 2: Third-Line Treatment of Relapsed/Refractory Follicular Lymphoma
This is Part 2 of Evolving Treatment Landscape of Indolent Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Laurie Sehn, Gilles Salles, and Sonali Smith discuss the third-line treatment of relapsed/refractory...
Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Novel CD19-1XX CAR With Calibrated Signaling in LBCL
In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Combination Immunotherapy Plus Radiotherapy in Muscle-Invasive Bladder Cancer
Studies show that although radical cystectomy has long been recognized as the standard-of-care for localized muscle-invasive bladder cancer (MIBC), the surgery carries significant morbidity and the risk of subsequent loss of quality of life for patients. Preclinical studies have suggested that a...
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Racial, Ethnic Disparities in Diagnostic Procedures Following Abnormal Mammograms
Investigators may have uncovered racial and ethnic disparities in the receipt of same-day diagnostic services and biopsies following abnormal mammogram findings in spite of the similar availability of diagnostic technologies, according to a recent study published by Lawson et al in Radiology....
Safety of Ceasing Combination Therapy After 2 Years in Patients With Renal Cell Carcinoma
Ceasing or pausing a combination of the immune checkpoint inhibitor nivolumab and the oral tyrosine kinase inhibitor (TKI) axitinib after 2 years may be safe among patients with metastatic renal cell carcinoma who achieved a positive response to this treatment, according to updated analysis of a...
Cancer, Aging, and Meaning: Navigating Psychosocial Challenges
I’ve learned a lot about medicine over the years, but one thing I wasn’t taught was how to guide someone through the existential weight of dying. My education centered on diagnosing, curing, or at least managing disease—not on the delicate art of helping people and their loved ones cope with what...
Merkel Cell Carcinoma: Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Disease
As reported in the Journal of Clinical Oncology by Bhatia et al, nivolumab/ipilimumab did not produce better outcomes vs nivolumab alone in a cohort of immune checkpoint inhibitor (ICI)-naive patients with recurrent or metastatic Merkel cell carcinoma (MCC) enrolled in the phase I/II CheckMate 358...
Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer
Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...
Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?
Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...
ctDNA and Immunoscore in Resected Stage III Colon Cancer
As reported in the Journal of Clinical Oncology by Taieb et al, a combined analysis of two phase III adjuvant trials (IDEA-France and IDEA-Greece) in stage III colon cancer showed that the presence of circulating tumor DNA (ctDNA) after surgery was prognostic for poorer outcomes and that...
Novel Blood Test May Help to Identify Pancreatic Ductal Adenocarcinoma at an Earlier Stage
A novel blood test may aid physicians in the earlier detection of pancreatic ductal adenocarcinoma and potentially improve survival rates for the disease, according to a recent study published by Montoya et al in Science Translational Medicine. Background Pancreatic ductal adenocarcinoma is the...
Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer
The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...
eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors
Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors, according to results from the registrational phase II eNRGy study published by Schram et al in The New England Journal of Medicine....
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
I’m a 2.0 Version of Myself After Cancer
Although there’s no history of breast cancer in my family, when I was 10, my pediatrician introduced me to breast self-exams, so I would become familiar with my breasts and learn to spot any unusual changes as I got older. I remember her telling me this was an especially important exercise to do...
Former UNMC Cancer Center Director, Kenneth H. Cowan, MD, PhD, Dies at 77
Kenneth H. Cowan, MD, PhD, served for 24 years as Director of the National Cancer Institute (NCI)-designated cancer center at the University of Nebraska Medical Center (UNMC), now called the Nebraska Medicine Fred & Pamela Buffett Cancer Center in Omaha. Dr. Cowan died on December 15, 2024, at ...
Felix Feng, MD, Leader in Genitourinary Cancer, Dies at Age 48
NRG Oncology, the RTOG Foundation, and the University of California, San Francisco (UCSF), announced the death of Felix Feng, MD, from cancer at age 48 on December 10, 2024. Dr. Feng was a George and Judy Marcus Distinguished Professor; Professor of Radiation Oncology, Urology and Medicine; Vice...
ARIEL4: Rucaparib vs Chemotherapy for Relapsed Ovarian Cancer With Deleterious BRCA1 or BRCA2 Mutations
In an article in The Lancet Oncology, Oza et al presented the final overall survival analysis of the phase III ARIEL trial of rucaparib vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma. Study Details In the open-label trial, 349 patients from sites in 12...
How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer
Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...
Primary Analysis of ZUMA-2: Bruton Tyrosine Kinase Inhibitor–Naive Relapsed or Refractory Mantle Cell Lymphoma
ZUMA-2 is a single-arm, multicenter, open-label phase II study that investigated leukapheresed adults with mantle cell lymphoma whose disease was refractory to or had relapsed after up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy; anti-CD20...
WHO, St. Jude Launch New Global Platform to Deliver Cancer Drugs to Pediatric Patients in Low-, Middle-Income Countries
The World Health Organization (WHO) and St. Jude Children’s Research Hospital have begun distributing critical cancer drugs to pediatric patients in two of six pilot countries through the new Global Platform for Access to Childhood Cancer Medicines. Background Every year, about 400,000 children...
ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
ASCO has updated its guidelines on the role of neoadjuvant chemotherapy for patients newly diagnosed with advanced ovarian cancer, underscoring key considerations in selecting patients for treatment and where to go from there.1 Since ASCO’s previous guidelines were published in 2016, there has been ...
Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology
Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL ...
New Blood-Based Screening Test Accurately Detects Colorectal Cancer Risk in Adults Aged 45 and Older
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.1 Although screening for colorectal cancer through colonoscopy or sigmoidoscopy is effective in detecting the...
Does Epstein-Barr Virus Increase Cancer Risk Among Kidney Transplant Recipients?
Kidney transplantation using donor organs carrying the Epstein-Barr virus may increase the risk of posttransplant lymphoproliferative disorder among recipients who have never been exposed to the virus, according to a recent study published by Potluri et al in the Annals of Internal Medicine....
Short- vs Standard-Course Radiation Therapy for Endometrial Cancer
Short-course, higher-dose vaginal brachytherapy for endometrial cancer may demonstrate comparable efficacy to more frequent, lower-dose sessions, according to a recent study published by Suneja et al in JCO Oncology Advances. Background Endometrial cancer is the most common cancer type of the...
